Cover Image
市場調查報告書

癌細胞激素治療藥的開發平台分析

Cancer Cytokines Therapy Pipeline Analysis

出版商 PNS Pharma 商品編碼 308690
出版日期 內容資訊 英文 231 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌細胞激素治療藥的開發平台分析 Cancer Cytokines Therapy Pipeline Analysis
出版日期: 2014年06月01日 內容資訊: 英文 231 Pages
簡介

隨著研究開發費的增加讓癌症療法應用的增加、技術的進步、專利到期、以及競爭激烈化,推動了癌細胞激素市場的成長。預測今後4∼5年製藥企業將更進一步將重點置於以細胞激素為主的癌症療法上。

本報告提供癌細胞因子治療市場相關調查,彙整市場概要,上市藥簡介·專利分析,Phase、國別臨床實驗分析,臨床開發階段的藥物,前臨床階段中佔多數的療法,已上市細胞因子治療,暫停、中止臨床實驗的藥物簡介及競爭情形等資料,為您概述為以下內容。

第1章 癌症細胞因子治療市場概要

第2章 癌症細胞因子治療臨床實驗分析:階段·國家·標的適應症

  • 未確認階段
  • 研究
  • 前臨床
  • 臨床
  • 階段I
  • 階段I/II
  • 階段II
  • 階段III

第3章 已上市癌細胞激素臨床簡介·專利分析

第4章 臨床實驗中暫停、中止的癌症細胞因子治療

  • 未開發
  • 中止
  • 停止

第5章 競爭情形

  • Altor BioScience
  • Biogenomics
  • Biosidus
  • Chiron Corporation (Novartis)
  • Expression Genetics
  • IRX Therapeutics
  • Philogen
  • Roche
  • Regulon
  • ZymoGenetics

圖表清單

目錄

Cytokines, a major group in the protein therapeutics umbrella, are known to be soluble extracellular proteins or glycoproteins which are crucial intercellular regulators, having the capacity to mobilize the cells which are engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. These proteins are being used mostly for cancer patients due to their capability to stop tumor growth. Cytokines are considered to be a large, diverse group of extracellular proteins which are produced by the immune system cells. These cytokines have the capacity to be bound by the cytokine receptors on the targeted cells. This process initiates a signaling cascade within those cells.

The growth in the cytokines market is mainly driven by its increased application for cancer treating methods, along with an increased spending on research and development, advances in technology, patent expiries, and rising competition. Cytokines are related to almost all the therapeutic protein drug development processes. The cytokine and growth factor related products include antibodies, proteins and nucleic acid probes which are being extensively used in a wide variety of applications from the basic research laboratory through the drug discovery process, to in vivo therapeutic use. The companies producing these proteins are focusing their strategy on offering high quality products at more than competitive prices.

It is expected that in the next 4-5 years, the pharma companies would focus more on the development of successful cancer therapies based on cytokines. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new cytokines products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. This segment has proved to be the most important investment to control the sprawling rise in cancer incidence rates. Also, from a commercial viewpoint, these cytokine products are likely to churn significant revenues and for the patient population, and eventually are expected to improve the survival rates and improve quality of life.

“Cancer Cytokines Therapy Pipeline Analysis” Report Highlights:

  • Cancer Cytokines Therapy Market Overview
  • Marketed Drug Profiles & Patent Analysis
  • Clinical Trial Insight by Phase & Country
  • Drug in Clinical Development Phase: 64
  • Majority Therapies in Preclinical Phase: 25
  • Marketed Cytokines Therapies: 15
  • Suspended & Discontinued Drug Profiles: 67
  • Competitive Landscape

Table of Contents

1. Cancer Cytokines Therapy Market Overview

  • 1.1. Market Overview
  • 1.2. Clinical Pipeline Insight

2. Cancer Cytokine Therapy Clinical Trial Insight by Phase, Country & Target Indications

  • 2.1. Unknown Phase
  • 2.2. Research
  • 2.3. Preclinical
  • 2.4. Clinical
  • 2.5. Phase I
  • 2.6. Phase I/II
  • 2.7. Phase II
  • 2.8. Phase III

3. Marketed Cancer Cytokines Clinical Profile & Patent Analysis

4. Suspended & Discontinued Cancer Cytokines Therapy in Clinical Trial

  • 4.1. No Development Reported
  • 4.2. Discontinued
  • 4.3. Suspended

5. Competitive Landscape

  • 5.1. Altor BioScience
  • 5.2. Biogenomics
  • 5.3. Biosidus
  • 5.4. Chiron Corporation (Novartis)
  • 5.5. Expression Genetics
  • 5.6. IRX Therapeutics
  • 5.7. Philogen
  • 5.8. Roche
  • 5.9. Regulon
  • 5.10. ZymoGenetics
  • Figure 1-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 1-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 1-3: No Development in Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 1-4: No Development in Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 1-5: Discontinued Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 1-6: Discontinued Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 1-7: Suspended Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 1-8: Suspended Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 5-1: Expression Genetics Clinical Pipeline
  • Figure 5-2: Philogen Clinical Pipeline

List of Tables

Following Information For Each Drug Profile in Covered in More than 200 Tables in Report:

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
Back to Top